美 「생물보안법(Biosecure Act)」 제정 추진에 따른 글로벌 바이오제약 분야 동향 및 시사점

Summary

The U.S. is pushing for the "Biosecure Act" to reduce its dependence on China for biopharmaceuticals and protect sensitive genetic data, driven by concerns over supply chain vulnerability and national security risks. This KISTEP brief analyzes the global biopharmaceutical market trends and supply chain realignments accelerated by the proposed Act, examining its implications and suggesting strategic responses for South Korea to emerge as a leading global bio-manufacturing nation. While the Act is still in progress (passed House, awaiting Senate approval), it has already led to decreased trust in Chinese bio firms, prompting some to consider divestment, and creating opportunities for companies in countries like South Korea to secure new contracts.

Key Facts

Source Document

https://example-government.gov/policy-document-link